-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Neuphoria Therapeutics, Lowers Price Target to $7

Benzinga·12/05/2025 12:55:39
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis maintains Neuphoria Therapeutics (NASDAQ:NEUP) with a Buy and lowers the price target from $21 to $7.